SLS•benzinga•
SELLAS Announces Data From Phase 2a Trial Of SLS009 In Combination With Zanubrutinib In DLBCL; Combination Achieved A 67% Of Overall Response Rate; Median Overall Survival Not Reached Yet, 67% Of Patients Still Alive
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 20, 2025 by benzinga